{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:30:49Z","timestamp":1794544249192,"version":"4.9.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI144004"],"award-info":[{"award-number":["AI144004"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS112727"],"award-info":[{"award-number":["NS112727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["R01CA249188"],"award-info":[{"award-number":["R01CA249188"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-OCRP"],"award-info":[{"award-number":["W81XWH-16-OCRP"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.molmet.2021.101272","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T06:25:33Z","timestamp":1623824733000},"page":"101272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Ovarian cancer modulates the immunosuppressive function of CD11b+Gr1+ myeloid cells via glutamine metabolism"],"prefix":"10.1016","volume":"53","author":[{"given":"Mary P.","family":"Udumula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharif","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha B.","family":"Alvero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouba","family":"Ali-Fehmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Abdulfatah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Buekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Munkarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramandeep","family":"Rattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.molmet.2021.101272_bib1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2020.05.681","article-title":"Immunotherapy for platinum-resistant ovarian cancer","volume":"158","author":"Bogani","year":"2020","journal-title":"Gynecologic Oncology"},{"issue":"Suppl 1","key":"10.1016\/j.molmet.2021.101272_bib2","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/annonc\/mdw084","article-title":"Opportunities in immunotherapy of ovarian cancer","volume":"27","author":"Coukos","year":"2016","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40425-019-0629-6","article-title":"Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer","volume":"7","author":"Liu","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"18","key":"10.1016\/j.molmet.2021.101272_bib4","first-page":"6076","article-title":"NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer","volume":"63","author":"Odunsi","year":"2003","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.molmet.2021.101272_bib5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2017.03.509","article-title":"NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer","volume":"145","author":"Szender","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"7353","key":"10.1016\/j.molmet.2021.101272_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research","year":"2011","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.molmet.2021.101272_bib7","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"13","key":"10.1016\/j.molmet.2021.101272_bib8","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/cncr.24317","article-title":"Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer","volume":"115","author":"Adams","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.molmet.2021.101272_bib9","series-title":"Medical imaging 2020: digital pathology","article-title":"Computer extracted features related to the spatial arrangement of tumor-infiltrating lymphocytes predict overall survival in epithelial ovarian cancer receiving adjuvant chemotherapy","author":"Azarianpour","year":"2020"},{"issue":"51","key":"10.1016\/j.molmet.2021.101272_bib10","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the U S A"},{"issue":"3","key":"10.1016\/j.molmet.2021.101272_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"10.1016\/j.molmet.2021.101272_bib12","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"15 Suppl","key":"10.1016\/j.molmet.2021.101272_bib13","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1200\/jco.2015.33.15_suppl.5509","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial [abstract]","volume":"33","author":"Disis","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1016\/j.molmet.2021.101272_bib14","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.molmet.2021.101272_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1479-5876-11-147","article-title":"Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer","volume":"11","author":"Lavou\u00e9","year":"2013","journal-title":"Journal of Translational Medicine"},{"issue":"Suppl 8","key":"10.1016\/j.molmet.2021.101272_bib16","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.molmet.2021.101272_bib18","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.molmet.2021.101272_bib19","series-title":"Neutrophils and granulocytic MDSC: the janus god of cancer immunotherapy","volume":"vol. 4","author":"Zilio","year":"2016"},{"key":"10.1016\/j.molmet.2021.101272_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","article-title":"Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment","volume":"128","author":"Parker","year":"2015","journal-title":"Advances in Cancer Research"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1084\/jem.20181170","article-title":"Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum","volume":"216","author":"Jae Lee","year":"2019","journal-title":"Journal of Experimental Medicine"},{"issue":"5","key":"10.1016\/j.molmet.2021.101272_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122311","article-title":"Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment","volume":"4","author":"Singel","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.molmet.2021.101272_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1016\/j.molmet.2021.101272_bib24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41416-019-0725-x","article-title":"Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment","volume":"122","author":"Horikawa","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1016\/j.molmet.2021.101272_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069631","article-title":"Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice","volume":"8","author":"Godoy","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.molmet.2021.101272_bib26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","article-title":"Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2","volume":"39","author":"Cui","year":"2013","journal-title":"Immunity"},{"issue":"7525","key":"10.1016\/j.molmet.2021.101272_bib27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nature13638","article-title":"Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer","volume":"515","author":"Di Mitri","year":"2014","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.molmet.2021.101272_bib28","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ncb1507","article-title":"Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis","volume":"8","author":"Hiratsuka","year":"2006","journal-title":"Nature Cell Biology"},{"issue":"7","key":"10.1016\/j.molmet.2021.101272_bib29","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.intimp.2011.01.030","article-title":"MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy","volume":"11","author":"Finke","year":"2011","journal-title":"International Immunopharmacology"},{"issue":"12","key":"10.1016\/j.molmet.2021.101272_bib30","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00262-020-02628-2","article-title":"The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer","volume":"69","author":"Komura","year":"2020","journal-title":"Cancer Immunology Immunotherapy"},{"issue":"13","key":"10.1016\/j.molmet.2021.101272_bib31","doi-asserted-by":"crossref","first-page":"11310","DOI":"10.18632\/oncotarget.3597","article-title":"Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer","volume":"6","author":"Khan","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.molmet.2021.101272_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells7070068","article-title":"Metabolic stress in the immune function of T cells, macrophages and dendritic cells","volume":"7","author":"Domblides","year":"2018","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.molmet.2021.101272_bib33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.04.005","article-title":"Metabolic pathways in immune cell activation and quiescence","volume":"38","author":"Pearce","year":"2013","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.molmet.2021.101272_bib34","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","article-title":"Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies","volume":"3","author":"Hossain","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","article-title":"Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer","volume":"28","author":"Li","year":"2018","journal-title":"Cell Metabolism"},{"issue":"5","key":"10.1016\/j.molmet.2021.101272_bib36","doi-asserted-by":"crossref","first-page":"e2779","DOI":"10.1038\/cddis.2017.192","article-title":"Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis","volume":"8","author":"Jian","year":"2017","journal-title":"Cell Death & Disease"},{"issue":"9","key":"10.1016\/j.molmet.2021.101272_bib37","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00262-018-2177-1","article-title":"mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells","volume":"67","author":"Deng","year":"2018","journal-title":"Cancer Immunology Immunotherapy"},{"key":"10.1016\/j.molmet.2021.101272_bib38","doi-asserted-by":"crossref","first-page":"20250","DOI":"10.1038\/srep20250","article-title":"mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors","volume":"6","author":"Wu","year":"2016","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.molmet.2021.101272_bib39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1189\/jlb.1VMR1216-535R","article-title":"Energy metabolic pathways control the fate and function of myeloid immune cells","volume":"102","author":"Al-Khami","year":"2017","journal-title":"Journal of Leukocyte Biology"},{"issue":"10","key":"10.1016\/j.molmet.2021.101272_bib40","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/2326-6066.CIR-18-0902","article-title":"Immunosuppressive immature myeloid cell generation is controlled by glutamine metabolism in human cancer","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.molmet.2021.101272_bib41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-015-0060-6","article-title":"Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer","volume":"3","author":"Liao","year":"2015","journal-title":"Journal of Immunotherapy Cancer"},{"issue":"13","key":"10.1016\/j.molmet.2021.101272_bib42","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.18632\/oncotarget.3434","article-title":"Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction","volume":"6","author":"Al-Wahab","year":"2015","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.molmet.2021.101272_bib43","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.18632\/oncotarget.2168","article-title":"Dietary energy balance modulates ovarian cancer progression and metastasis","volume":"5","author":"Al-Wahab","year":"2014","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.molmet.2021.101272_bib44","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1172\/JCI131859","article-title":"Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells","volume":"130","author":"Oh","year":"2020","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1016\/j.molmet.2021.101272_bib45","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4049\/jimmunol.1501549","article-title":"AMP-activated protein kinase suppresses autoimmune central nervous system disease by regulating M1-type macrophage-Th17 Axis","volume":"197","author":"Mangalam","year":"2016","journal-title":"The Journal of Immunology"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcph.1275","article-title":"Pharmacometabolomics reveals irinotecan mechanism of action in cancer patients","volume":"59","author":"Bao","year":"2019","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"52","key":"10.1016\/j.molmet.2021.101272_bib47","doi-asserted-by":"crossref","first-page":"30697","DOI":"10.1074\/jbc.M115.679068","article-title":"Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis","volume":"290","author":"Poisson","year":"2015","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib48","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1038\/s41598-017-09206-0","article-title":"Bioenergetic adaptations in chemoresistant ovarian cancer cells","volume":"7","author":"Dar","year":"2017","journal-title":"Scientific Reports"},{"issue":"23","key":"10.1016\/j.molmet.2021.101272_bib49","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1158\/0008-5472.CAN-13-1550","article-title":"Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Research"},{"issue":"7\u20138","key":"10.1016\/j.molmet.2021.101272_bib50","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.intimp.2009.03.015","article-title":"Gemcitabine directly inhibits myeloid derived suppressor cells in BALB\/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice","volume":"9","author":"Le","year":"2009","journal-title":"International Immunopharmacology"},{"issue":"18","key":"10.1016\/j.molmet.2021.101272_bib51","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.molmet.2021.101272_bib52","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1096\/fj.201802067RR","article-title":"Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment","volume":"33","author":"Zeng","year":"2019","journal-title":"The FASEB Journal"},{"issue":"5","key":"10.1016\/j.molmet.2021.101272_bib53","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.3802\/jgo.2017.28.e64","article-title":"Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer","volume":"28","author":"Zhu","year":"2017","journal-title":"J\u00a0Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semcancer.2005.07.005","article-title":"Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression","volume":"16","author":"Serafini","year":"2006","journal-title":"Seminars in Cancer Biology"},{"key":"10.1016\/j.molmet.2021.101272_bib55","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3389\/fimmu.2019.01273","article-title":"Myeloid derived suppressor cells: key drivers of immunosuppression in ovarian cancer","volume":"10","author":"Baert","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41416-019-0644-x","article-title":"Energy metabolism manipulates the fate and function of tumour myeloid-derived suppressor cells","volume":"122","author":"Hu","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"9","key":"10.1016\/j.molmet.2021.101272_bib57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","volume":"20","author":"Leone","year":"2020","journal-title":"Nature Reviews Cancer"},{"issue":"12","key":"10.1016\/j.molmet.2021.101272_bib58","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.bbapap.2016.06.014","article-title":"NAD(+) metabolism: bioenergetics, signaling and manipulation for therapy","volume":"1864","author":"Yang","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.molmet.2021.101272_bib59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40170-017-0165-0","article-title":"The alpha-ketoglutarate dehydrogenase complex in cancer metabolic plasticity","volume":"5","author":"Vatrinet","year":"2017","journal-title":"Cancer & Metabolism"},{"issue":"16","key":"10.1016\/j.molmet.2021.101272_bib60","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/1873-3468.12777","article-title":"Physiological levels of formate activate mitochondrial superoxide\/hydrogen peroxide release from mouse liver mitochondria","volume":"591","author":"Young","year":"2017","journal-title":"FEBS Letters"},{"issue":"7","key":"10.1016\/j.molmet.2021.101272_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040677","article-title":"Myeloid suppressor cell depletion augments antitumor activity in lung cancer","volume":"7","author":"Srivastava","year":"2012","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.molmet.2021.101272_bib62","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.molmet.2021.101272_bib63","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.molimm.2008.08.266","article-title":"Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression","volume":"46","author":"Bak","year":"2008","journal-title":"Molecular Immunology"},{"issue":"9","key":"10.1016\/j.molmet.2021.101272_bib64","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/nm1097","article-title":"Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A","volume":"10","author":"Conejo-Garcia","year":"2004","journal-title":"Nature Medicine"},{"issue":"13","key":"10.1016\/j.molmet.2021.101272_bib65","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1158\/0008-5472.CAN-05-3755","article-title":"CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/2326-6066.CIR-19-0315","article-title":"Myeloid cells orchestrate systemic immunosuppression, impairing the efficacy of immunotherapy against HPV(+) cancers","volume":"8","author":"Galliverti","year":"2020","journal-title":"Cancer Immunology Research"},{"issue":"4","key":"10.1016\/j.molmet.2021.101272_bib67","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5114\/ceji.2017.72823","article-title":"Myeloid-derived suppressor cells in ovarian cancer: friend or foe?","volume":"42","author":"Walankiewicz","year":"2017","journal-title":"Central European Journal of Immunology"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib68","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1038\/s41467-019-10015-4","article-title":"Competition for nutrients and its role in controlling immune responses","volume":"10","author":"Kedia-Mehta","year":"2019","journal-title":"Nature Communications"},{"issue":"7858","key":"10.1016\/j.molmet.2021.101272_bib69","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.molmet.2021.101272_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1344804","article-title":"Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells","volume":"6","author":"Al-Khami","year":"2017","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.molmet.2021.101272_bib71","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc.2016.114","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.molmet.2021.101272_bib72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","article-title":"Glutaminolysis: a hallmark of cancer metabolism","volume":"19","author":"Yang","year":"2017","journal-title":"Annual Review of Biomedical Engineering"},{"issue":"1","key":"10.1016\/j.molmet.2021.101272_bib73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn","year":"2017","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"4","key":"10.1016\/j.molmet.2021.101272_bib74","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.molmet.2021.101272_bib75","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ajhg.2019.04.010","article-title":"Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas","volume":"104","author":"Remacha","year":"2019","journal-title":"The American Journal of Human Genetics"},{"issue":"6","key":"10.1016\/j.molmet.2021.101272_bib76","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/leu.2016.26","article-title":"The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis","volume":"30","author":"Anderson","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.molmet.2021.101272_bib77","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/carcin\/bgy033","article-title":"Ovarian cancer therapeutic potential of glutamine depletion based on GS expression","volume":"39","author":"Furusawa","year":"2018","journal-title":"Carcinogenesis"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877821001174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877821001174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:29:04Z","timestamp":1761956944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877821001174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":77,"alternative-id":["S2212877821001174"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2021.101272","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian cancer modulates the immunosuppressive function of CD11b+Gr1+ myeloid cells via glutamine metabolism","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2021.101272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"101272"}}